Charles River Laboratories’ manufacturing arm delivered a large revenue jump in the first quarter of the year owing to an uptick in customer activity.
The company also noted that it expects to benefit from the Biosecure Act. “We are an alternative for folks that either can’t or don’t want to continue to do their work in China. So, I think directionally it is something positive to watch. We would be surprised if it doesn’t have a benefit to us,” CEO James Foster said during its Thursday morning earnings call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.